FindTrial
Sign In

Atevirdine mesylate

DRUG4 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID), Pharmacia and Upjohn

Conditions

HIV Infections

Phase 1

A Phase I Concentration-Controlled Trial to Assess the Safety, Tolerance, Pharmacokinetics and Development of Decreased HIV-1 Susceptibility to the Combination of Atevirdine Mesylate (U-87201E), Zidovudine (AZT), and Didanosine (ddI)
CompletedNCT00000742
National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections
End: 1993-10-31Target: 15Updated: 2021-11-04
A Phase I Concentration-Targeted Multidose Study of Atevirdine Mesylate ( U-87201E ), AZT, and ddI or ddC
CompletedNCT00000753
National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections
End: 1995-02-28Target: 30Updated: 2021-11-04

Phase 2

A Study of Different Doses of Atevirdine Mesylate Plus Zidovudine in HIV-Positive Patients
CompletedNCT00002322
Pharmacia and UpjohnHIV Infections
Updated: 2005-06-24

Unknown Phase

Prospective Open-Label Study of the Emergence of Drug Resistance in Patients Infected With HIV-1 Who Are Taking Oral U-87201E
CompletedNCT00002094
Pharmacia and UpjohnHIV Infections
Updated: 2005-06-24